Commercialization
As the global leader in biosimilars, Sandoz has unparalleled market experience in a range of market types. It also enjoys strong commercial synergies due to its unique position within the Novartis Group, with Novartis Pharma leading commercialization in selected markets and providing support for government affairs and market access.The Sandoz brand, the roots of which go back to 1886, is also a major asset worldwide; key historical successes include the first orally administered form of penicillin in 1951, the groundbreaking transplant drug cyclosporine in the 1970s, and the production in 1980 of one of the first recombinant proteins, an interferon.
All these developments, culminating in today’s broad portfolio of differentiated generics and the first-ever biosimilars, have contributed to make Sandoz a supplier of choice – reflecting our broad experience, customer focus, and culture of “continuous innovation”.
